SHR-4640

Summary

Shr-4640 (CHEMBL3746329) is a phase-3 clinical-stage small molecule; indicated across 3 conditions including gout and liver disorder.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 3 conditions
• Clinical trials: 18
• Chemistry: 338.22 Da · C14H12BrNO2S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL3746329
Name	SHR-4640
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	86294127
Molecular formula	C14H12BrNO2S
Molecular weight	338.22
InChIKey	QGBWIYLNOBYNDL-UHFFFAOYSA-N

SMILES: C1CC(C1)(C(=O)O)SC2=C3C=C(C=CC3=NC=C2)Br

IUPAC name: 1-(6-bromoquinolin-4-yl)sulfanylcyclobutane-1-carboxylic acid

Also known as: Ruzinurad, Shr-4640, SHR-4640, Shr4640, SHR4640

Patent coverage: 11 distinct patent families (32 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 22 (69%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: Solute carrier family 22 member 12.

Bioactivity

ChEMBL activities: 5 potent at pChembl ≥ 5 of 5 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
SLC22A12	7.72	IC50	19	nM	CHEMBL_ACT_27209324
SLC22A12	7.48	IC50	33	nM	CHEMBL_ACT_18070375
SLC22A12	7.47	IC50	33.7	nM	CHEMBL_ACT_16429191
SLC22A12	7.47	IC50	33.7	nM	CHEMBL_ACT_25704117
SLC22A12	7.28	IC50	53	nM	CHEMBL_ACT_29153317

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

3 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
gout	3	MONDO:0005393	EFO:0004274
liver disorder	1	MONDO:0005154	EFO:0001421

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 18.

Phase distribution

Phase	Trials
PHASE1	12
PHASE2	4
PHASE3	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04052932	PHASE3	COMPLETED	A Study of Evaluating the Efficacy and Safety of SHR4640 in Subjects With Gout
NCT04956432	PHASE3	COMPLETED	A Multicentre, Randomized, Double-blind, Allopurinol Controlled Study to Evaluate the Efficacy and Safety of SHR4640 in Subjects With Gout
NCT07362355	PHASE2	RECRUITING	The Efficacy and Safety of SHR4640 Tablet Combined With 40 mg Febuxostat Tablets in the Treatment of Primary Gout and Hyperuricemia
NCT03185793	PHASE2	COMPLETED	Dose-finding and Safety Study of SHR4640 in Subjects With Hyperuricemia
NCT04180982	PHASE2	UNKNOWN	A Safety and Efficacy Study of SHR4640 and Febuxostat in Subjects With Hyperuricemia
NCT05513976	PHASE2	UNKNOWN	Clinical Study of SHR4640 Tablets Combined With Febuxostat Tablets in the Treatment of Primary Gout and Hyperuricemia
NCT02815839	PHASE1	COMPLETED	Single Dose Study of SHR4640 in Healthy Subjects
NCT02890966	PHASE1	COMPLETED	Multiple Dose Study of SHR4640 in Healthy Subjects
NCT03015948	PHASE1	COMPLETED	A Single Dose Study of SHR4640 in Healthy Male Volunteers
NCT03131583	PHASE1	COMPLETED	The Drug-Drug Interaction of SHR4640, Febuxostat and Colchicine in Patients With Gout
NCT03211403	PHASE1	COMPLETED	Multiple Doses Study of SHR4640 in Male Subjects With High Serum Uric Acid Level
NCT04157959	PHASE1	UNKNOWN	The Drug-Drug Interaction of SHR4640 and Febuxostat in Patients With Hyperuricemia
NCT04305392	PHASE1	UNKNOWN	Pharmacokinetics, Pharmacodynamics and Safety of SHR4640 in Patients With Hepatic Impairment
NCT04586803	PHASE1	UNKNOWN	Study on the Bioavailability of Three Different Prescription Processes of SHR4640 Tablets in Healthy Volunteers
NCT04620408	PHASE1	UNKNOWN	Study on the Food Effects of Oral SHR4640 Tablets in Healthy Volunteers
NCT04850638	PHASE1	COMPLETED	Drug Interaction Between SHR4640 Tablets and Furosemide Tablets in Healthy Volunteers (Single Center, Single Arm, Open, Self-control)
NCT05954169	PHASE1	COMPLETED	Pharmacokinetic/Pharmacokinetic and Safety Studies of SHR4640 in Subjects With Moderate Renal Insufficiency and Healthy Subjects
NCT06168929	PHASE1	COMPLETED	Bioequivalence Study of 2 Sizes of SHR4640 Tablets Orally in Healthy Subjects

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).